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Abstract. Psoriasin (S100A7) is an 11-kDa small calcium 
binding protein initially isolated from psoriatic skin lesions. 
It belongs to the S100 family of proteins which play an impor-
tant role in a range of cell functions including proliferation, 
differentiation, migration and apoptosis. Aberrant Psoriasin 
expression has been implicated in a range of cancers and is 
often associated with poor prognosis. This study examined 
the role of Psoriasin on pancreatic cancer cell functions and 
the implication in progression of the disease. Expression of 
Psoriasin was determined in a cohort of pancreatic tissues 
comprised of 126 pancreatic tumours and 114 adjacent 
non-tumour pancreatic tissues. Knockdown and overexpres-
sion of Psoriasin in pancreatic cancer cells was performed 
using specifically constructed plasmids, which either had 
anti-Psoriasin ribozyme transgene or the full length human 
Psoriasin coding sequence. Psoriasin knockdown and overex-
pression was verified using conventional RT-PCR and qPCR. 
The effect of manipulating Psoriasin expression on pancreatic 
cancer cell functions was assessed using several in vitro cell 
function assays. Local invasive pancreatic cancers extended 
beyond the pancreas expressed higher levels of Psoriasin 
transcripts compared with the cancers confined to the 
pancreas. Primary tumours with distant metastases exhibited 
a reduced expression of Psoriasin. Psoriasin overexpres-
sion cell lines exhibited significantly increased growth and 
migration compared to control cells. In addition, Psoriasin 
overexpression resulted in increased pancreatic cancer cell 
invasion which was associated with upregulation of matrix 
metalloproteinase-2 (MMP-2) and MMP-9. Overexpression 
of Psoriasin also promoted aggregation and survival of 
pancreatic cancer cells when they lost anchorage. Taken 
together, higher expression of Psoriasin was associated with 
local invasion in pancreatic cancers. Psoriasin expression is 
associated with pancreatic cancer cell growth, migration, 
cell-matrix adhesion, and invasion via regulation of MMPs. 
As such, the proposed implications of Psoriasin in invasion, 
disease progression and as a potential therapeutic target 
warrant further investigation.
Introduction
Psoriasin, also known as S100A7, is a member of the S100 
protein family of calcium binding proteins and was first 
identified as being overexpressed in psoriatic skin lesions (1). 
It is a 11.4-kDa secretory protein encoded on chromo-
some 1q21, clustered alongside 16 other members of the S100 
family within a region known as the epidermal differen-
tiation complex (EDC) (2,3). The S100 family encodes both 
cytoplasmic and secreted proteins that share EF-hand helix-
loop-helix domains, important for their role as calcium binding 
proteins (4). Psoriasin S100 proteins are widely expressed in 
numerous cell types localised to the cytoplasm and/or nucleus, 
or in some cases are secreted. Due to their role in calcium 
binding and signalling, they are involved in numerous cell 
functions including proliferation, differentiation, migration 
and apoptosis.
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In addition to its overexpression in psoriatic skin lesions, 
aberrant Psoriasin expression has been implicated in a range of 
human diseases including cancer. Interestingly, Psoriasin is a 
chemotactic factor for keratinocytes and leukocytes (5-7), and 
is also upregulated and excreted from cells of the epidermis 
during inflammation. Additionally, Psoriasin has been impli-
cated as an antimicrobial peptide, selectively killing E. coli 
on the surface of the skin (8). Therefore, Psoriasin may be 
utilised, via the host immune response, as a selective chemo-
tactic factor both in psoriasis and cancer (9).
The expression of Psoriasin during carcinogenesis has been 
studied in detail, and its overexpression has been linked to a 
number of cancers including breast (10), prostate (11), skin (12), 
head and neck (13), bladder (14) and lung cancer (15). It is also 
often associated with poor prognosis. For example in breast 
cancer, Psoriasin expression correlates with features of poor 
prognosis, including oestrogen receptor (ER) and progesterone 
receptor (PR) negativity, hER2 positivity, and the presence of 
lymphocytic infiltration (16-18). The precise role of Psoriasin 
in cancer remains unclear. One hypothesis links Psoriasin 
expression with stimulation of angiogenesis regulated by 
vEGF (19). In the development of breast cancer, Psoriasin 
regulates epidermal growth factor (EGF)-induced phos-
phorylation of the EGF receptor (EGFR), actin remodelling 
and NF-κβ mediated matrix metalloproteinase-9 (MMP-9) 
secretion, promoting tumour development and metastasis (20). 
These results suggest Psoriasin plays an important role in 
carcinoma development.
Pancreatic cancer is the fourth leading cause of cancer 
deaths in Western countries and carries a very poor prognosis 
due to delayed diagnosis and lack of effective treatments. 
The majority of patients present with metastasis at diag-
nosis; 25% with local metastasis and 55% with regional 
metastasis (21). The most common sites of metastasis are the 
liver, followed by the peritoneum, lung and pleura, bones and 
adrenal glands. Outcome for patients is poor with a 5-year 
survival rate of <5% (22). In comparison to the studies of other 
malignancies, pancreatic cancer requires more intensive study 
for understanding genetic and molecular machinery which 
is utilised by cancerous cells during disease progression and 
metastasis. This study aimed to examine the role of Psoriasin 
in pancreatic cancer with a focus for its involvement in local 
invasion and distant metastasis.
Materials and nethods
Materials and cell lines. Pancreatic cell lines (MIA-PaCa-2 
and PANC-1) were purchased from the American Type 
Culture Collection (ATCC, Rockville, MD, USA). Both cell 
lines are derived from primary tumours of pancreatic cancer. 
MIA-PaCa-2 was isolated from a pancreatic carcinoma 
while PANC-1 was derived from an epithelioid carcinoma 
of pancreas. The pancreatic cancer cells were maintained 
in Dulbecco's modified Eagle's medium (DMEM)-F12 
medium, supplemented with 10% fetal calf serum (FCS) and 
antibiotics. LP-9 mesothelial cells were purchased from the 
Coriell Institute for Medical Research (Camden, NJ, USA) and 
maintained in M199 medium supplemented with 15% FCS 
and antibiotics. Matrigel (BD Matrigel Basement Membrane 
Matrix) was obtained from BD Biosciences (Oxford, UK).
Construction of ribozyme transgenes targeting human 
Psoriasin and Psoriasin overexpression vectors. Anti-human 
Psoriasin hammerhead ribozymes were designed based on the 
secondary structure of the mRNA generated using Zuker's 
RNA Mfold program (23). The ribozymes were synthe-
sized and cloned into pEF6/v5-his-TOPO plasmid vector 
(Invitrogen, Paisley, UK). The primers used for ribozyme 
synthesis are shown in Table I. Similarly, full-length human 
Psoriasin coding sequence amplified from normal human 
prostate tissues was cloned into the same vector. Constructed 
plasmids were extracted using the Genelute Plasmid Mini-Prep 
kit (Sigma-Aldrich, Poole, UK). Ribozyme transgenes, over-
expression constructs, and control plasmids were transfected 
into MIA-PaCa-2 and PANC-1 cells by electroporation 
(Gene Pulser Xcell; Bio-Rad, hertfordshire, UK). Stable 
transfectants were obtained and verified following two weeks 
selection using blasticidin (5 µg/ml, Melford Laboratories Ltd., 
Suffolk, UK). The cells were then cultured in DMEM with 
blasticidin at a lower concentration (0.5 µg/ml) to maintain 
plasmid expression.
RNA isolation, reverse transcription-PCR (RT-PCR) and 
quantitative PCR (qPCR). Total RNA was isolated using 
TRI reagent (Sigma-Aldrich). First strand cDNA synthesis 
was undertaken using the Precision nanoScript Reverse 
Transcription kit (Primer Design, Southampton, UK). PCR 
was performed using GoTaq Green MasterMix (Promega, 
Dorset, UK). Cycling conditions were as follows: 94˚C for 
5 min followed by 36 cycles of 94˚C for 30 sec, 55˚C for 30 sec, 
and 72˚C for 40 sec. This was followed by a final extension of 
72˚C for 10 min. Products were visualised using 2% agarose 
gels stained with SYBR Safe (Invitrogen).
qPCR was performed using the Icycler Iq5 system 
(Bio-Rad, hammel hempsted, UK). Pancreatic cancer cell 
cDNA samples were examined for Psoriasin transcript expres-
sion, alongside a set of standards and negative controls. The 
Amplifluor system (Intergen Inc., Oxford, UK) and qPCR 
mastermix (Bio-Rad) were used. Psoriasin primer pairs were 
designed using Beacon design software (Premier Biosoft, 
Palo Alto, CA, USA), whereby the reverse primer contained 
an additional Z sequence (5'-ACTGAACCTGACCGTACA) 
complementary to the universal Z probe (Intergen Inc.). 
Reaction conditions were as follows: 94˚C for 12 min, followed 
by 90 cycles of 94˚C for 15 sec, 55˚C for 40 sec and 72˚C for 
20 sec.
Quantification of Psoriasin transcripts in human pancreatic 
cancer. human pancreatic tissue was collected from patients 
undergoing surgical resection of pancreatic tumours at the 
Beijing Cancer hospital. The specimens retrieved comprised 
126 pancreatic tumours and 114 along with matched adjacent 
normal pancreatic tissues over a period from 2002 to 2011 
with follow-up information up to 2013 (median, 12 months, 
IqR, 6-20.5 months). The tissues were stored immediately 
after surgery at -80˚C until use. Clinicopathological factors, 
including age, sex, histological type, TNM stage, lymph node 
metastasis, distant metastases and embolism, were recorded 
and stored in the patient database. The protocol and procedure 
were reviewed and approved by the Beijing Cancer hospital 
Research Ethics Committee and written consent was obtained 
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from all patients involved. Total RNA extraction was then 
performed using TRI reagent (Sigma-Aldrich). Psoriasin tran-
scripts were determined using qPCR together with an internal 
control keratin 19 (CK19). Normalised Psoriasin transcript 
levels are shown in Table II. Primer sequences are provided 
in Table I.
In vitro cell growth assay. A standard growth assay was under-
taken as previously described (15,24). Cells were plated into a 
96-well plate (3,000 cells/well) and growth was assessed after 
1, 3 and 5 days. Crystal violet was used to stain the cells, and 
absorbance was determined at a wavelength of 540 nm using a 
spectrophotometer (Elx800; Bio-Tek, Bedfordshire, UK).
Electric cell-substrate impedance sensing (ECIS) based 
cellular migration assays. An ECIS-Ztheta instrument 
(Applied Biophysics Ltd.; Troy, NJ, USA) was used with a 
96-well 96W1E microarrays and wounding module. Pancreatic 
cancer cells were seeded at 40,000 cells per well and cell 
adhesion was tracked immediately over a range of frequencies 
from 1,000 to 64,000 Hz. Once the cells reached confluence, a 
current of 2,600 µA was passed across each well for 20 sec to 
produce a reproducible wound, after which cell migration was 
automatically tracked.
Cell-matrix adhesion assay. A total of 20,000 cells were 
added to each well of a 96-well plate previously prepared by 
coating with Matrigel (5 µg/well). The cells were incubated 
at 37˚C in 5% CO2 for 45 min and the medium was then 
discarded. Non-adherent cells were washed off using balanced 
salt solution (BSS) buffer. Adherent cells were then fixed in 
4% formalin, stained with crystal violet and absorbance deter-
mined at 540 nm.
Cell-cell adhesion assay. LP-9 mesothelial cells were tryp-
sinised and transferred to a 96-well plate at 30,000 cells 
per well and grown to confluence over a 24-h period. 




Psoriasin (expression) 5'-ATGAGCAACACTCAAGCTG 5'-ACTGGCTGCCCCCGGAACA
Psoriasin (QPCR) 5'-TGTGACAAAAAGGGCACAAA 5'-ACTGAACCTGACCGTACACCCAGCAAGGACA
  GAAACTC
CK19 (QPCR) 5'-CAGGTCCGAGGTTACTGAC 5'-ACTGAACCTGACCGTACACCGTTTCTGCCAGT 
  GTGTCTTC
Cyclin D1 5'-CGGTGTCCTACTTCAAATGT 5'-ACCTCCTCCTCCTCCTCT
p27Kip1 5'-GGAATAAGGAAGCGACCTG 5'-CCGTCTGAAACATTTTCTTC
Caspase 3 5'-GGCGTGTCATAAAATACCAG 5'-ACAAAGCGACTGGATGAA
MMP9 5'-AACTACGACCGGGACAAG 5'-ATTCACGTCGTCCTTATGC
GAPDH 5'-GGCTGCTTTTAACTCTGGTA 5'-AGCAAGGACAGAAACTCAGA
Psoriasin (ribozyme) 5'-CTGCAGTCACAGGCACTAAGGAA 5'-ACTAGTGGCTGGTGTTTGACATTTCGTCCTCA
 GTTGGGCTGATGAGTCCGTGAGGA CGGACT
Table II. Psoriasin transcript levels in pancreatic cancer.
 N Mean ± SEM p-value
  (copies/25 ngRNA)
Clinical samples
  Tumour 126   162.9±75.8 0.32
  Normal 114 1,7793±17,660
histology
  Adeno 108   134.7±79
  Ductal 4      981±981 0.45 vs adeno
  Others 14      147±147 0.94 vs adeno
T staging
  1 2     1.77±1.77
  2  19   0.847±0.799
  3 73   184.5±97.6 0.064 vs T2
  4  10      644±640
  T1-2  21 
  T3-4  83      240±114 0.04
Node status
  Node-negative  46      272±166
  Node-positive 4     1.77±1.77 0.11
Metastasis
  Yes 9 0.00014±0.00010
  No 117   175.5±81.5 0.033
Clinical outcome
  Died 89     90.1±64.3
  Alive 26      402±283 0.29
Embolism
  Yes 35      212±162
  No 73      179±105 0.87
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Pancreatic cancer cells were stained with 10 µg/ml DiI 
membrane stain (1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-
carbocyanine perchlorate, Life Technologies) before being 
added at 20,000 cells per well to the mesothelial cell mono-
layer. Pancreatic cancer cells were left to adhere for 40 min 
before non-adherent cells were washed off using BSS buffer. 
Adherent cells were then fixed (4% formalin) and images were 
taken at 549 excitation/565 emission and phase contrast using 
an EvOS FL auto (Life Technologies), before the total number 
of adherent pancreatic cancer cells was counted.
In vitro invasion assay. Transwell inserts with 8 µm pore size 
(Greiner Bio-One, Gloucester, UK) were coated with 50 µg 
Matrigel and air-dried before being rehydrated. A total of 
20,000 cells were added to each insert. Following 72-h incuba-
tion, cells that had migrated through the matrix and pores were 
fixed (4% formalin), stained in crystal violet and absorbance 
determined at 540 nm.
Gelatin zymography assay. Pancreatic cancer cells (3x106) 
were seeded into a 75-cm2 flask. Following overnight culture, 
cells were washed twice with serum-free DMEM and cultured 
in serum-free DMEM for 6 h. The conditioned medium was 
then collected by centrifugation to remove any cells. Samples 
were prepared in non-reducing sample buffer (containing 
0.625 mM Tris-hCl, 10% glycerol, 2% SDS, and 2% bromo-
phenol blue). Each sample (30 µl) was loaded into each lane 
and separated by 10% sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) on gels containing 1 mg/ml 
gelatine (Sigma-Aldrich). The gel was then renatured at room 
temperature in washing buffer (containing 2.5% Triton X-100 
and 0.02% NaN3), before being incubated in a buffer containing 
50 mM Tris-hCl (ph 7.6), 5 mM CaCl2, and 0.02% NaN3 for 
72 h before staining with Coomassie blue. The clear bands 
of gelatin digested by MMPs was documented and analysed 
using densitometry.
Cell aggregation assay. Cell aggregation was measured over 
a time course of 3 h, at 1 h intervals. MiaPa-Ca-1 cells with 
varying Psoriasin expression were harvested using trypsin. 
A small amount was aliquoted for initial measurements. 
The remaining solution was left at 37˚C, on a tilt table, to 
prevent adherence. The collected samples were kept on ice to 
prevent additional aggregation. Cells were aliquoted out at 1, 
2 and 3 h. Cell aggregation was measured using a Neubauer 
haemocytometer (Celeromics, Cambridge, UK) under a light 
microscope, with total individual cells counted followed by 
the number of cell groups.
Anoikis assay. Cells (250,000-500,000) per experiment 
were transferred to a fresh UC and spun down in a centri-
fuge at 1700 rpm for 5 min and washed with ice-cold PBS 
and re-centrifuged. The cells were suspended in 250 µl of 
Annexin v binding (Invitrogen) buffer per 250,000 cells. This 
solution (100 µl) was mixed with 5 µl of pre-mixed staining 
solution (0.2 µl propidium iodide, 0.8 µl Annexin v-FITC, 4 µl 
Annexin v binding buffer) (Invitrogen) and left in the dark, at 
room temperature, for 30 min. It was then diluted with 400 µl 
of filtered PBS and kept on ice. The remaining cell solution 
was incubated at 37˚C at 5% CO2 and the process repeated at 
1 and 2 h. The samples were then run through a flow cytometer 
(Cyflow, Sysmex UK Ltd.).
Western blot analysis. Equal amount of total proteins of each 
cell line was separated on an SDS-PAGE gel. The proteins were 
then electrically transferred on to a nitrocellulose membrane 
and probed with anti-caspase 3 and GAPDh antibodies 
(Santa Cruz Biotechnology, CA, USA), respectively, and also 
corresponding peroxidase conjugated secondary antibodies 
(Sigma-Aldrich). Images of the protein bands were devel-
oped using a chemiluminescence detection kit (Luminata, 
Millipore) and a UvITech imager (UvITech, Inc.).
Statistical analysis. Statistical analysis was performed 
using SPSS18 (SPSS Inc., Chicago, IL, USA). The t-test and 
Mann-Whitney U test were used for normally distributed and 
non-normally distributed data respectively. Kaplan-Meier 
analysis was used to analyse the correlation with patient 
survival. Differences were considered statistically significant 
at p<0.05.
Results
Expression of Psoriasin in pancreatic cancer, and evaluation 
of Psoriasin levels in cell lines. In the search of gene expres-
sion array data base at PubMed, a reduction was seen in the 
expression of Psoriasin in pancreatic cancers in comparison 
with the paired adjacent normal pancreatic tissues (GDS4336)
(Fig. 1A). We further determined the transcript levels of 
Psoriasin in a cohort of 126 pancreatic tumours and 114 adja-
cent normal pancreatic tissues. Psoriasin expression appeared 
to be reduced in the tumours but did not reach a significant level 
in comparison with the adjacent normal tissues (Table II). An 
even lower expression of Psoriasin was seen in tumours with 
distant metastases. Interestingly, higher Psoriasin transcript 
levels were seen in locally invasive tumours which extended 
beyond the pancreas (T3 and T4) in comparison with tumours 
confined to the pancreas (T1 and T2) (Table II). It suggests that 
Psoriasin plays a significant role in regulation of invasion of 
pancreatic cancer cells. To clarify the involvement of Psoriasin 
in metastasis, we analysed the expression of Psoriasin in 
another gene expression array of pancreatic tumours which 
includes 145 primary tumours and 61 metastatic tumours 
(GSE71729) (25). An increased expression of Psoriasin was 
seen in the secondary tumours in comparison with its expres-
sion in primary tumours (Fig. 1B).
The mRNA expression of Psoriasin in three different pancre-
atic cancer cell lines was evaluated using RT-PCR (Fig. 1C). 
RAGE, the receptor of Psoriasin was detected in the three 
pancreatic cancer cell lines. PCR products of 528 bp were 
amplicons of both variant 2 and 4, while 480-bp products 
represented amplicons from variant 1, 3, 5, 6, 7, 8 and 9. 
however, exact variants expressed in these cell lines are yet to 
be further determined (Fig. 1C). The expression of Psoriasin 
in MIA-PaCa-2 is higher than that for PANC-1, and lowest in 
AsPc-1. Psoriasin knockdown and overexpression was verified 
in the MIA-PaCa-2 and PANC-1 cell lines transfected with 
ribozyme transgenes using RT-PCR (Fig. 1D) and qPCR 
(Fig. 1E). The Psoriasin-modified MIA-PaCa-2 and PANC-1 
cell lines were used for subsequent experiments.
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Effect of Psoriasin knockdown and overexpression on pancre-
atic cancer cell growth and migration. A significant decrease 
in cellular growth was observed in Psoriasin knockdown 
MIA-PaCa-2 (Fig. 2A, p<0.001) and PANC-1 (Fig. 2B, p<0.05) 
cell lines in comparison with controls. Conversely, overexpres-
sion of Psoriasin resulted in increased growth of MIA-PaCa-2 
and PANC-1 cell lines (p<0.05).
Psoriasin knockdown resulted in decreased migration of 
MIA-PaCa-2 (Fig. 2C, p<0.001) and PANC-1 (Fig. 2D, p<0.05) 
cell lines compared to controls. Conversely, Psoriasin over-
Figure 1. Expression of Psoriasin in pancreatic cancer and pancreatic cancer cell lines with altered Psoriasin expression. (A) Reduced expression of Psoriasin 
was seen in a cohort of 45 pancreatic ductal adenocarcinomas in comparison with its expression in the paired adjacent normal pancreatic tissues (GDS4336) (26). 
(B) An elevated expression of Psoriasin was seen in metastases of pancreatic cancer compared with its expression in primary tumours (GSE71729) (25). 
(C) Psoriasin and RAGE transcripts were detected in PANC-1, AsPC-1 and MIA-PaCa-2 cell lines using conventional PCR. Knockdown and overexpression of 
Psoriasin were performed using anti-Psoriasin ribozyme transgenes and a recombinant plasmid vector carrying full-length human Psoriasin coding sequence, 
respectively. The altered expression of Psoriasin in the transfected pancreatic cancer cell lines (MIA-PaCa-2 and PANC-1) was verified using conventional 
PCR (D) and real-time PCR (E). *p<0.05, **p<0.01.
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expression resulted in increased migration of MIA-PaCa-2 
(p<0.001) and PANC-1 (p<0.05) cell lines.
Influence of Psoriasin expression on pancreatic cancer 
cell adhesion. An in vitro cell-matrix adhesion assay was 
adopted to investigate the effect of Psoriasin knockdown and 
overexpression on the adhesive ability of pancreatic cancer 
cells to extracellular matrix. MIA-PaCa-2 (Fig. 3A, p<0.05) 
and PANC-1 (Fig. 3B, p<0.05) Psoriasin overexpressing cells 
exhibited decreased cell-matrix adhesion whilst Psoriasin 
knockdown resulted in increased adhesion to matrix (p<0.05).
According to the involvement in adhesion of pancreatic 
cancer cells, we were curious about a possible implication in 
dissemination through peritoneal cavity. Therefore, we deter-
mined the effect of Psoriasin expression on pancreatic cancer 
cell adhesion to mesothelial which constitute peritoneum. 
Neither Psoriasin overexpression nor knockdown had any 
significant effect on the adhesion of PANC-1 cells to perito-
neal mesothelia compared to control (Fig. 3C).
Effect of Psoriasin expression on pancreatic cancer cell inva-
sion. The influence of Psoriasin expression on MIA-PaCa-2 
and PANC-1 cell invasion was examined. Interestingly, 
Psoriasin overexpression resulted in increased invasion 
of MIA-PaCa-2 (Fig. 4A, p<0.001) and PANC-1 (Fig. 4B, 
p<0.05) cell lines whilst Psoriasin knockdown resulted in 
decreased invasion of MIA-PaCa-2 (p<0.001) and PANC-1 
(p<0.05) cells.
At the mRNA level, MMP-9 expression was significantly 
increased in Psoriasin overexpression MIA-PaCa-2 cells 
compared to controls (Fig. 4C). Conversely, MMP-9 expres-
sion was decreased in Psoriasin knockdown MIA-PaCa-2 
cells. As the results from zymography show, MMP-2 and 
Figure 2. Effect of Psoriasin on proliferation and migration of pancreatic cancer cell lines. The influence on cell proliferation was determined over a period up 
to five days. Impact on in vitro proliferation was determined for MIA-PaCa-2 (A) and PANC-1 (B) cell lines a colorimetric method. The migration of pancreatic 
cancer cell lines were measured using ECIS for MIA-PaCa-2 (C) and for PANC-1 (D). Six repeats were included for each cell line and three independent 
experiments were performed. Growth rate was calculated against the corresponding day 0 control. *p<0.05, **p<0.01.
Figure 3. Influence on adhesion of pancreatic cancer cell lines. (A) Adhesion 
of MIA-PaCa-2 cells was altered by the knockdown and overexpression of 
Psoriasin. (B) Impact on cell adhesion of PANC-1 cell by the differential 
expression of Psoriasin. (C) Adhesion of PANC-1 cells to the peritoneal 
mesothelial cells. Adhesion rate was calculated based on the number of cells 
seeded. Six repeats were included for each cell line and three independent 
experiments were performed. *p<0.05.
INTERNATIONAL JOURNAL OF ONCOLOGY  50:  1491-1500,  2017 1497
MMP-9 activity is increased in Psoriasin overexpression 
MIA-PaCa-2 cells compared to control (Fig. 4D), whilst 
MMP-2 and MMP-9 activity is decreased in Psoriasin knock-
down MIA-PaCa-2 cells. As shown in Fig. 4C, decreased 
Psoriasin expression resulted in the decreased expression 
of cyclin D2 at the mRNA level in MIA-PaCa-2 cells in 
which an increased level of p27Kip1 was also noted. Moreover, 
overexpression of Psoriasin resulted in increased cyclin D2 
expression.
Influence of Psoriasin on aggregation and survival of pancre-
atic cancer cells. In order to evaluate how MIA-PaCa-2 cells 
interact with one another in suspension, a cell aggregation 
assay was performed. Cells with increased Psoriasin expres-
sion demonstrated an increased propensity to form cell-cell 
contacts whilst in suspension, reaching significance at 3 h 
(Fig. 5, p<0.05). To determine whether this observation had 
an impact on the anoikis resistance in this cell line, an apop-
tosis assay was performed. We observed cell survival after 
suspension was increased in Psoriasin overexpressing cell 
lines (Fig. 6). Western blot analyses of adherent cells showed 
an enhanced activation of caspase-3 in MIA-PaCa-2 cells as 
cleaved proteins in comparison with the control (Fig. 7). A 
reduction in the cleavage of caspase-3 was not observed in 
the Psoriasin overexpression cells compared with the control 
which also exhibited a lower level of the activation.
Discussion
Psoriasin was first identified as being overexpressed in the 
hyperproliferative skin disease psoriasis. Numerous studies 
have since demonstrated Psoriasin overexpression to be asso-
ciated with tumour progression. Upregulation of Psoriasin 
in cancer was initially identified in pre-invasive carcinomas; 
whether this upregulation occurs in pancreatic intra-epithelial 
neoplasia progression that proceeds to pancreatic adenocarci-
noma remains to be elucidated. Increased Psoriasin expression 
has also been identified in cancers at an advanced stage. In 
breast cancer, Psoriasin overexpression is associated with 
metastasis and poor prognosis. In the present study, Psoriasin 
expression was determined in a cohort of pancreatic cancer 
patients. Psoriasin expression tended to be reduced in the 
Figure 4. Psoriasin and invasion of pancreatic cancer cell lines. The invasion of MIA-PaCa-2 (A) and PANC-1 (B) cell lines were determined using a Transwell 
invasion assay in triplicates. (C) Expression of MMP-2, p27Kip1, cyclin D2 and caspase-3 was detected in MIA-PaCa-2 cells with differential expression of 
Psoriasin using conventional PCR. (D) Active MMP-2 and MMP-9 were determined using gelatine zymography. Invasion rates were calculated against 
corresponding control in which the same number of cells were seeded at beginning of the experiments. Three independent experiments were performed. 
*p<0.05, **p<0.01.
Figure 5. Psoriasin and aggregation of pancreatic cancer cells. Aggregation 
of MIA-PaCa-2 cells was determined over a duration ≤3 h. Three indepen-
dent experiments were performed. *p<0.05.
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pancreatic cancers compared to adjacent normal pancreatic 
tissues, though did not reach statistical significance. This obser-
vation is similar to findings from a GEO data set (GDS4336) 
(Fig. 1A) (26). A reduced expression was noted in primary 
tumours (n=9) with distant metastases. This finding is yet to 
be verified by examining of a large cohort pancreatic primary 
tumours with a reasonable number of primary tumours which 
have distant metastasis. In an analysis of a gene expression 
array data, an increased expression levels of Psoriasin was 
seen in metastases of pancreatic cancer in comparison with 
primary tumours (Fig. 1B). Interestingly, a greater expres-
sion of Psoriasin was evident in locally advanced pancreatic 
tumours. It suggests that Psoriasin may play differential roles 
during the development and progression of the disease, in 
particular, the metastatic process.
We determined the expression of Psoriasin in the cell lines 
AsPc-1, MIA-PaCa-2 and PANC-1, and expression appeared 
highest in MIA-PaCa-2 which is the most tumourigenic of the 
three cell lines (27). These results demonstrate that Psoriasin 
overexpression is associated with increased cancer cell growth 
in vitro, whilst knockdown inhibits growth. Interestingly, during 
breast cancer progression, Psoriasin has been shown to interact 
with Jab1 (c-jun activation-domain binding protein), which is 
involved in proteosomal degradation and signal transduction. 
Interaction between Psoriasin and Jab1 results in increased 
activator protein-1 (AP-1) activity, increased expression of 
AP-1 and hIF-1-dependent genes, and reduced expression of 
the cell cycle inhibitor p27Kip1, resulting in enhanced tumouri-
genesis and metastasis in vivo (28). It may be that in pancreatic 
cancer, the same mechanisms are taking place promoting 
tumour growth and metastasis. Jab1 is a negative regulator of 
p27Kip1, promoting its degradation (29). p27Kip1 normally binds 
to and prevents the activation of cyclin complexes controlling 
cell cycle progression at G1 (30). Thus, it may be that increased 
interaction between Psoriasin and Jab1 results in decreased 
p27Kip1. In line with this, an increased expression of p27Kip1 was 
also observed in the Psoriasin knockdown cells (Fig. 4C). We 
also found that Psoriasin overexpression results in increased 
expression of cyclin D2, which may explain the mode of action 
for Psoriasin-mediated promotion of cyclin activation and cell 
cycle progression. Additionally, differential expression of 
RAGE, the receptor of Psoriasin was seen in three pancreatic 
cancer cell lines. RAGE has 8 isoforms of protein products 
encoded by 9 different splicing variants in humans (listed 
at PubMed Gene). however, we cannot identify which vari-
Figure 6. Psoriasin and anoikis of pancreatic cancer cells. Apoptosis of suspension MIA-PaCa-2 cells with altered expression of Psoriasin was determined 
using a flow cytometric method.
Figure 7. Caspase 3 in MIA-PaCa-2 cells were detected using western blot 
analysis.
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ants were expressed by these cell lines. The exact role played 
by RAGE in mediating functions of Psoriasin in pancreatic 
cancer is yet to be investigated.
In this study, Psoriasin expression was inversely linked to 
cell-matrix adhesion. This is similar to our results observed in 
both prostate and lung cancer (11,15). It suggests that expres-
sion of Psoriasin is a response by cancer cells to changes of 
cell-matrix adhesion and reciprocally affects cell adhesion to 
matrix. We also found Psoriasin expression has no effect on 
the adhesion of pancreatic cancer cells to peritoneal mesothe-
lial in vitro, and conclude that Psoriasin may not be required 
for the adhesion during peritoneal metastasis of pancreatic 
cancer.
Psoriasin is regarded as an inflammation-associated 
protein and has chemoattractant properties, promoting 
migration of granulocytes, lymphocytes, macrophages and 
monocytes. Our study showed Psoriasin overexpression results 
in increased migration of pancreatic cancer cells. The multi-
ligand receptor for advanced glycation end-products (RAGE) 
has been identified as a Psoriasin receptor, and implicated in 
leukocyte migration and the inflammatory process. It may 
be that, similar to leukocyte migration, Psoriasin attaches to 
RAGE in order to promote cancer cell migration (5).
Further to its influences on cell growth, adhesion and 
migration, we also examined the effect of Psoriasin on pancre-
atic cancer cell invasion. It is well known that activation of 
MMP-2 and MMP-9 promotes the invasive and metastatic 
potential of pancreatic cancer cells (31,32). In our recent study 
of Psoriasin in prostate cancer, Psoriasin has been shown to 
have an effect on prostate cancer cell invasion via MMPs (11). 
This is subsequently confirmed herein, whereby Psoriasin 
overexpression in pancreatic cancer cells resulted in increased 
MMP-2 and MMP-9 expression and activity. Taken together, 
these data suggest Psoriasin regulates invasion of pancre-
atic cancer cells via regulation of MMPs. In a recent study, 
Morgan et al observed interaction between Psoriasin and the 
cytoplasmic domain of the integrin β6 subunit is required for 
αvβ6-dependent breast cancer cell invasion. Similarly, they 
showed upregulation of MMPs in Psoriasin overexpressing 
breast cancer cells (33). In line with its higher expression levels 
in local invasive tumours, Psoriasin promotes invasion of 
pancreatic cancer cells which leads to a greater local invasive 
expansion of the disease.
A recent report of disruption of cell anchorage inducing 
apoptosis led us to investigate whether Psoriasin has a role 
of inducing this form of anoikis resistance in pancreatic 
cancer cells (34). Anoikis is referred to as a programmed cell 
death or apoptosis which happens to adherent cells lacking 
anchorage (34). It can occur during the dissemination of 
pancreatic cancer cells through circulation and peritoneal 
cavity when they lose anchorage. At 3 h we saw a significant 
rise of cell-cell aggregates, indicating a role for Psoriasin in 
inducing these aggregates. Previous experiments showed a role 
for Psoriasin in preventing anoikis (34), a result we confirmed 
in our cell lines, hinting that cell-cell aggregation may 
contribute to preventing anoikis. Despite this, based on our 
results, the number of cell-cell aggregates show a significant 
increase only at 3 h, whereas cells display anoikis resistance at 
1 h, indicating other mechanisms must be at play to compen-
sate for the disparity. Western blot analyses of adherent cells 
showed an increased activation of caspase 3 in the Psoriasin 
knockdown MIA-PaCa-2 cells. The involvement of intrinsic 
and extrinsic caspase pathways and activation of caspase-3 in 
pancreatic cancer cells undergoing anoikis remains unclear 
and is yet to be investigated. Further investigation is also 
required to reveal molecules involved in the enhanced cell-cell 
adhesion and aggregation.
In conclusion, reduced expression of Psoriasin was seen in 
pancreatic cancers with distant metastases, whilst higher tran-
script levels were seen in locally advanced tumours. Psoriasin 
expression in pancreatic cancer cells is associated with cell 
growth, cell-matrix adhesion and migration. Psoriasin regu-
lates invasion of pancreatic cancer cells via expression of 
MMPs. The implication of Psoriasin expression in invasion, 
disease progression and potential as a therapeutic target 
warrants further investigation.
Acknowledgements
The authors thank the support from Cancer Research Wales, 
Life Sciences Research Network Wales (Welsh Government's 
Ser Cymru Program) and Albert huang Foundation. Ying Liu, 
Yanan Gu and Gang Chen are recipients of China Medical 
Scholarship from the Cardiff University.
References
  1. Madsen P, Rasmussen hh, Leffers h, honoré B, Dejgaard K, 
Olsen E, Kiil J, Walbum E, Andersen Ah, Basse B, et al: 
Molecular cloning, occurrence, and expression of a novel 
partially secreted protein "psoriasin" that is highly up-regulated 
in psoriatic skin. J Invest Dermatol 97: 701-712, 1991.
  2. hoffmann hJ, Olsen E, Etzerodt M, Madsen P, Thøgersen hC, 
Kruse T and Celis JE: Psoriasin binds calcium and is upregulated 
by calcium to levels that resemble those observed in normal skin. 
J Invest Dermatol 103: 370-375, 1994.
  3. Børglum AD, Flint T, Madsen P, Celis JE and Kruse TA: Refined 
mapping of the psoriasin gene S100A7 to chromosome 1cen-q21. 
hum Genet 96: 592-596, 1995.
  4. Schäfer BW and heizmann CW: The S100 family of EF-hand 
calcium-binding proteins: Functions and pathology. Trends 
Biochem Sci 21: 134-140, 1996.
  5. Wolf R, howard OM, Dong h-F, voscopoulos C, Boeshans K, 
Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B, et al: 
Chemotactic activity of S100A7 (Psoriasin) is mediated by the 
receptor for advanced glycation end products and potentiates 
inflammation with highly homologous but functionally distinct 
S100A15. J Immunol 181: 1499-1506, 2008.
  6. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC and 
Morel F: IL-22 inhibits epidermal differentiation and induces 
proinflammatory gene expression and migration of human kera-
tinocytes. J Immunol 174: 3695-3702, 2005.
  7. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, 
Garcia M, venereau E, Preisser L, Guignouard E, et al: 
Oncostatin M secreted by skin infiltrating T lymphocytes is a 
potent keratinocyte activator involved in skin inflammation. 
J Immunol 178: 4615-4622, 2007.
  8. Gläser R, harder J, Lange h, Bartels J, Christophers E and 
Schröder JM: Antimicrobial psoriasin (S100A7) protects human 
skin from Escherichia coli infection. Nat Immunol 6: 57-64, 
2005.
  9. Jinquan T, vorum h, Larsen CG, Madsen P, Rasmussen hh, 
Gesser B, Etzerodt M, honoré B, Celis JE and Thestrup-
Pedersen K: Psoriasin: A novel chemotactic protein. J Invest 
Dermatol 107: 5-10, 1996.
10. Jiang WG, Watkins G, Douglas-Jones A and Mansel RE: 
Psoriasin is aberrantly expressed in human breast cancer and is 
related to clinical outcomes. Int J Oncol 25: 81-85, 2004.
11. Ye L, Sun Ph, Martin TA, Sanders AJ, Mason MD and Jiang WG: 
Psoriasin (S100A7) is a positive regulator of survival and invasion 
of prostate cancer cells. Urol Oncol 31: 1576-1583, 2013.
LIU et al:  PSORIASIN IN PANCREATIC CANCER1500
12. Moubayed N, Weichenthal M, harder J, Wandel E, Sticherling M 
and Gläser R: Psoriasin (S100A7) is significantly up-regulated 
in human epithelial skin tumours. J Cancer Res Clin Oncol 133: 
253-261, 2007.
13. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, 
Shukla NK, Duggal R, DattaGupta S, Ralhan R, et al: Nuclear 
S100A7 is associated with poor prognosis in head and neck 
cancer. PLoS One 5: e11939, 2010.
14. Celis JE, Rasmussen hh, vorum h, Madsen P, honoré B, Wolf h 
and Orntoft TF: Bladder squamous cell carcinomas express 
psoriasin and externalize it to the urine. J Urol 155: 2105-2112, 
1996.
15. hu M, Ye L, Ruge F, Zhi X, Zhang L and Jiang WG: The clinical 
significance of Psoriasin for non-small cell lung cancer patients 
and its biological impact on lung cancer cell functions. BMC 
Cancer 12: 588, 2012.
16. Enerbäck C, Porter DA, Seth P, Sgroi D, Gaudet J, Weremowicz S, 
Morton CC, Schnitt S, Pitts RL, Stampl J, et al: Psoriasin expres-
sion in mammary epithelial cells in vitro and in vivo. Cancer Res 
62: 43-47, 2002.
17. Emberley ED, Alowami S, Snell L, Murphy LC and Watson Ph: 
S100A7 (psoriasin) expression is associated with aggressive 
features and alteration of Jab1 in ductal carcinoma in situ of the 
breast. Breast Cancer Res 6: R308-R315, 2004.
18. Watson Ph, Leygue ER and Murphy LC: Psoriasin (S100A7). Int 
J Biochem Cell Biol 30: 567-571, 1998.
19. Shubbar E, vegfors J, Carlström M, Petersson S and Enerbäck C: 
Psoriasin (S100A7) increases the expression of ROS and vEGF 
and acts through RAGE to promote endothelial cell proliferation. 
Breast Cancer Res Treat 134: 71-80, 2012.
20. Sneh A, Deol YS, Ganju A, Shilo K, Rosol TJ, Nasser MW and 
Ganju RK: Differential role of psoriasin (S100A7) in estrogen 
receptor α positive and negative breast cancer cells occur through 
actin remodeling. Breast Cancer Res Treat 138: 727-739, 2013.
21. Jemal A, Siegel R, Ward E, hao Y, Xu J and Thun MJ: Cancer 
statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
22. Gadiya M, Mori N, Cao MD, Mironchik Y, Kakkad S, 
Gribbestad IS, Glunde K, Krishnamachary B and Bhujwalla ZM: 
Phospholipase D1 and choline kinase-α are interactive targets in 
breast cancer. Cancer Biol Ther 15: 593-601, 2014.
23. Zuker M: Mfold web server for nucleic acid folding and hybrid-
ization prediction. Nucleic Acids Res 31: 3406-3415, 2003.
24. Bonnekoh B, Wevers A, Jugert F, Merk h and Mahrle G: Colori-
metric growth assay for epidermal cell cultures by their crystal 
violet binding capacity. Arch Dermatol Res 281: 487-490, 1989.
25. Moffitt RA, Marayati R, Flate EL, volmar KE, Loeza SG, 
hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung Ah, 
et al: virtual microdissection identifies distinct tumor- and 
stroma-specific subtypes of pancreatic ductal adenocarcinoma. 
Nat Genet 47: 1168-1178, 2015.
26. Zhang G, he P, Tan h, Budhu A, Gaedcke J, Ghadimi BM, 
Ried T, Yfantis hG, Lee Dh, Maitra A, et al: Integration of 
metabolomics and transcriptomics revealed a fatty acid network 
exerting growth inhibitory effects in human pancreatic cancer. 
Clin Cancer Res 19: 4983-4993, 2013.
27. Deer EL, González-hernández J, Coursen JD, Shea JE, Ngatia J, 
Scaife CL, Firpo MA and Mulvihill SJ: Phenotype and genotype 
of pancreatic cancer cell lines. Pancreas 39: 425-435, 2010.
28. Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC 
and Watson PH: Psoriasin interacts with Jab1 and influences 
breast cancer progression. Cancer Res 63: 1954-1961, 2003.
29. Tomoda K, Kubota Y and Kato J: Degradation of the cyclin-
dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 
398: 160-165, 1999.
30. Sgambato A, Cittadini A, Faraglia B and Weinstein IB: Multiple 
functions of p27(Kip1) and its alterations in tumor cells: A 
review. J Cell Physiol 183: 18-27, 2000.
31. Ellenrieder v, Alber B, Lacher U, hendler SF, Menke A, 
Boeck W, Wagner M, Wilda M, Friess h, Büchler M, et al: Role 
of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J 
Cancer 85: 14-20, 2000.
32. Zhang K, Chen D, Jiao X, Zhang S, Liu X, Cao J, Wu L and 
Wang D: Slug enhances invasion ability of pancreatic cancer 
cells through upregulation of matrix metalloproteinase-9 and 
actin cytoskeleton remodeling. Lab Invest 91: 426-438, 2011.
33. Morgan MR, Jazayeri M, Ramsay AG, Thomas GJ, Boulanger MJ, 
hart IR and Marshall JF: Psoriasin (S100A7) associates 
with integrin β6 subunit and is required for αvβ6-dependent 
carcinoma cell invasion. Oncogene 30: 1422-1435, 2011.
34. Dey KK, Sarkar S, Pal I, Das S, Dey G, Bharti R, Banik P, 
Roy J, Maity S, Kulavi I, et al: Mechanistic attributes of S100A7 
(psoriasin) in resistance of anoikis resulting tumor progression in 
squamous cell carcinoma of the oral cavity. Cancer Cell Int 15: 
74, 2015.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International (CC BY-NC-ND 4.0) License.
